Deutsche Bank upgraded Pediatrix Medical to Hold from Sell with an unchanged price target of $8. The analyst has increased conviction in the company’s potential hit 2025 EBITDA of $220M due to savings from divestitures. The firm also cites valuation for the upgrade. However, it believes Pediatrix’s core EBITDA is still in a structural decline and sees it declining again in 2026.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MD: